. 1998 Jul;42(7):1620–1628. doi: 10.1128/aac.42.7.1620

TABLE 2.

Antiviral drug susceptibilities of recombinant HIV from patients whose viruses developed RT mutations while the patient was receiving adefovir dipivoxil monotherapy

Patient	Time point	Recombinant virus sequence^a	IC₅₀ (μM)^b
Patient	Time point	Recombinant virus sequence^a	Adefovir	AZT	3TC	Ritonavir
A	Baseline	A98S, E122K, I135V/I, R211K, L214F, P272A, R277K, T286A, E297A	8.0	0.05	1.6	0.010
	6 mo	K70E, A98S, E122K, I135V/I, R211K, L214F, R277K/R, E297A/E	24.5	0.05	5.0	0.013
B	Baseline	E122K, I142V, L214F	9.3	0.005	0.5	0.010
	6 mo	K43R, E122K, I142V, E204G/E, R211K, L214F, T215I	4.7	0.28	0.7	0.015
C	Baseline	T69N, K70R, R83K, E122K, I135T, S162C, Q207E, L214F, V245K	18.7	0.57	1.5	0.013
	12 mo	M41L, T69N, R83K, A98S, E122K, S162C, T200A, Q207E, L214F, T215Y	19.0	1.60	1.5	0.009
D	Baseline	E122K, I135V, S162C, G196V, R211K, L214F, V276T	10.4	0.14	1.8	0.028
	12 mo	D67N,K70R, E122K, I135V/I, I142V, S162C, G196V, R211K, L214F, T215Y/N	90.0	3.5	10.5	0.029
E	Baseline	V35I/V, A98S/A, E122K, S134R/S, G141R/G, Q207E, R211K, L214F, P272A	7.7	0.15	1.3	0.014
	6 mo	V35I, T69D, A98S/A, E122K, Q207E, R211K, L214F, P272A/P, L289P/L	13.1	0.1	2.7	0.011
		HXB2D wild-type recombinant	15.5	0.25	2.6	0.014
		K70E site-directed recombinant	76.0	0.20	7.0	0.018
		T69D site-directed recombinant	45.0	0.50	35.0	0.020

Underlining indicates RT sequences with amino acid changes from baseline that are potentially associated with adefovir dipivoxil therapy. Slashes indicate mixtures of wild-type and mutant amino acids.

IC₅₀s are averages for three to six independent experiments; average standard errors were <10%.